No6(5) 2022
Back to the issue
|
DOI 10.37219/2528-8253-2022-6-66 |
Deyeva JuV
Evaluation of the clinical efficacy of anti-inflammatory therapy with
topical biclotymol-based products |
Dieieva Julia V.
MD, PhD, professor
Head of the department of Otorhinolaryngology
Bogomolets National Medical University, Kiev
E-mail: deyeva@bigmir.net
ORCID ID: 0000-0003-0552-1254
https://www.scopus.com/authid/detail.uri?authorId=55359076200 |
|
Abstract
Topicality: Acute pharyngeal diseases are one of the most common
reasons for patients to visit a doctor.
According to the UK, approximately 50% of these diseases account for the
appointment of antibacterial agents.
Most of these prescriptions are not rational, but doctors use them for
several reasons - unreal expectations of treatment, patient
pressure/insistence on conducting the desired tests or treatment, the
doctor's desire to maintain a better doctor-patient relationship, limited
consultation time, diagnostic uncertainty, incorrect collection of
historical data and others. Despite these reasons, patients with acute
pharyngitis and tonsillitis who seek antibiotic therapy want to reduce their
symptoms. Therefore, the search for agents that will significantly improve
patients' quality of life during acute pharyngeal diseases is crit ical.
Aim: To review the literature on the therapeutic efficacy of topical
biclotymol-based products for treating acute pharyngeal diseases.
Results and discussion: Most cases of acute pharyngitis should be
treated with over-the-counter medicines that are primarily intended to
control the symptoms of the disease and improve the patient's quality of
life. Biclotymol, enoxolone and lysozyme are novel substances that, at the
same time, are safe for resolving pain in viral or bacterial pharyngit is.
Biclotymol can be used as monotherapy and in combination with other agents.
In the analysed data, biclotymol showed its therapeutic efficacy and safety.
Therefore, it is safe to recommend biclotymolbased products for use in acute
viral and bacterial pharyngitis or tonsillitis both as monocomponent
medicine and fixed-dose combination. |
|
Keywords
acute pharyngitis, acute tonsillitis, treatment, Biclotimol. |
|
Reference
- Chorna VV, Khliestova SS, Gumeniuk NI, Makhniuk VM, Sydorchuk TM.
[Morbidity indicators and dissemination and modern attitudes on disease
prevention]. Reports of the Vinnytsia National Medical University.
2020;24(1):158-64. doi:10.31393/reports-vnmedical-2020-24(1)-31.
[Article in Ukrainian].
- Worrall GJ. Acute sore throat. Can Fam Physician.
2007;53(11):1961-2.
- Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas, and
Bennett’s Principles and Practice of Infectious Diseases. 7th ed.
Elsevier; 2015. Bryant AE, Stevens DL. Streptococcus pyogenes; p.
2285-99.
- Dolk FCK, Pouwels KB, Smith DRM, Robotham JV, Smieszek T.
Antibiotics in primary care in England: which antibiotics are prescribed
and for which conditions? J Antimicrob Chemother. 2018;
73(suppl_2):ii2-ii10. doi: 10.1093/jac/dkx504.
- Little P, Dorward M, Warner G, Stephens K, Senior J, Moore M.
Importance of patient pressure and perceived pressure and perceived
medical need for investigations, referral, and prescribing in primary
care: nested observational study. BMJ. 2004;328 (7437):444. doi:
10.1136/bmj.38013.644086.7C.
- van Driel ML, De Sutter A, Deveugele M, Peersman W, But ler CC, De
Meyere M, et al. Are sore throat patients who hope for antibiotics
actually asking for pain relief? Ann Fam Med. 2006;4(6): 494-9. doi:
10.1370/afm.609.
- van der Velden AW, Bell J, Sessa A, Duerden M, Altiner A. Sore
throat: effective communication delivers improved diagnosis, enhanced
self-care and more rational use of antibiotics. Int J Clin Pract Suppl.
2013;67(180):10-6. doi:10.1111/ijcp.12336.
- Masheyko AM. [Analysis of the incidence of acute pharyngitis and
tonsillitis and their poststreptococcal complications in children in
Ukraine]. Social pharmacy in health care. 2017; 3(1):14-22. doi:
10.24959/sphhcj.17.73. [Article in Ukrainian].
- Shafranskyi VV. [Annual report on the state of health of the
population, the sanitary-epidemic situation and the results of the
health care system of Ukraine]. State institution "Ukrainian institute
of strategic research of the Ministry of health of
Ukraine"; 2016. 452 p. [In Ukrainian].
- Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat.
Cochrane Database Syst Rev. 2013; 2013(11):CD000023. doi:
10.1002/14651858.CD000023.pub4.
- Carapetis J, Bowen A, May P. The inequitable burden of group A
streptococcal diseases in Indigenous Australians: we need to fill
evidence gaps and make clinical advances to reduce these diseases of
disadvantage (Report). Med J Aust. 2016;205(5):201-3. doi:
10.5694/mja16.00400.
- Oliver JR, Pierse N, Stefanogiannis N, Jackson C, Baker MG. Acute
rheumatic fever and exposure to poor housing conditions in New Zealand:
A descriptive study. J Paediatr Child Health. 2017 Apr;53(4):358-364.
doi: 10.1111/jpc.13421.
- ESCMID Sore Throat Guideline Group, Pelucchi C, Grigoryan L, Galeone
C, Esposito S, Huovinen P, Little P, Verheij T. Guideline for the
management of acute sore throat. Clin Microbiol Infect. 2012;18 Suppl
1:1-28. doi: 10.1111/j.1469-
0691.2012. 03766.x.
- SchammÒ‘e B, Couvrat N, Malpeli P, Dudognon E, Delbreilh L, Dupray V,
Dargent, E, Coquerel G. Transformation of an active pharmaceutical
ingredient upon high energy milling: A process-induced disorder in
Biclotymol. Int J Pharm. 2016;499(1-2):67-73. doi:
10.1016/j.ijpharm.2015.12.032.
- Deeva YV. [The results of complex application drugsHexalyse and
Hexaspray in the treatment of inflammatory diseases of the throat]
Family Medicine. 2015;58(2):149-52. [Article in Ukrainian].
- Chevalier E. [Etude en double aveugle contre placebo de l’activitи
therapeutique de Hexaspray dans les angines et pharyngites aigues].
Gazette Medicale 1987;94:73-5. [Article in French].
- Karpova E, Giacomelli L, Tumietto F. Role of biclotymol-based
products in the treatment of infectious sore throat. Eur Rev Med
Pharmacol Sci. 2017;21(16):3736-3743.
- Fuji HY, Tian J, Luka C. Effect of glycyrrhetinic acid on influenza
virus and pathogenic bacteria. Trends in Pharmacological Sciences.
1986;(1): 238-41.
- Lin JC. Mechanism of action of glycyrrhizic acid in inhibition of
EpsteinBarr virus replication in vitro. Antiviral Res. 2003;59(1):41-7.
doi: 10.1016/s0166-3542(03)00030-5.
- Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci.
2010;35(1):127-60. doi: 10.1007/s12038-010-0015-5.
- Cartel F, Cartei G, Ceschia V, Pacor S, Sava G. Recovery of
lymphocyte CD4+:CD8+ratio in patients treated with lysozyme. Drug
Investig. 1992; (4):51-7.
https://doi.org/10.1007/BF03258379.
- Gallo D, Cocchietto M, Masat E, Agostinis C, Harei E, Veronesi P, et
al. Human recombinant lysozyme downregulates advanced glycation
endproduct-induced interleukin-6 production and release in an in-vitro
model of human proximal tubular epithelial cells. Exp Biol Med
(May-wood). 2014;239(3):337-46. doi: 10.1177/1535370213518281.
- Bergamo A, Gerdol M, Pallavicini A, Greco S, Schepens I, Hamelin R,
et al. Lysozyme-induced transcriptional regulation of TNF-αpathway genes
in cells of the monocyte lineage. Int J Mol Sci. 2019;20(21):5502. doi:
10.3390/ijms20215502.
- Tagashira A, Nishi K, Matsumoto S, Sugahara T. Anti-inflammatory
effect of lysozyme from hen egg white on a mouse peritoneal macrophages.
Cytotechnology. 2018;70(3):929-38. doi: 10.1007/s10616-017-0184-2.
- Del Mar CB, Glasziou PP, Spinks AB. Ant ibiot ics for sore throat.
Cochrane Database Syst Rev. 2006; (4):CD000023.
doi:10.1002/14651858.CD000023.pub3.
- Oxford JS, Leuwer M. Acute sore throat revisted: clinical and
experimental evidence for efficacy of over-the-counter AMC/DCBA throat
lozenges. Int J Clin Pract. 2011;65(5):524-30. doi:
10.1111/j.1742-1241.2011.02644.x.
|
|